Randomized, open-label, cross-over, phase-3 study to evaluate efficacy and safety of LIB003 compared with evolocumab in homozygous familial hypercholesterolaemia patients on stable lipid-lowering therapy (liberate-HOFH)

Articles > Article · 2023

Authors: F. Raal, V. Mehta, M. Kayikcioglu, D. Blom, P. Gupta, C. Daniels, J. Vest, K. Caldwell, E.M. Bahassi, D. Kallend, E. Stein

Atherosclerosis, International, WoS, 2023, vol 379, pp S24-S25